Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487195 | 0.80 | TDP1 (0.51) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL4487187 | 0.80 | TDP1 (0.51) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL4487191 | 0.80 | TDP1 (0.51) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL28811226 | 0.80 | TSHR (0.54) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL4474269 | 0.80 | TDP1 (0.55) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL4485881 | 0.79 | ALDH1A1 (0.56) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL1702849 | 0.79 | MAPK1 (0.56) | TSHRLMNAMAPTALDH1A1KDM4E | |
| SCHEMBL15063756 | 0.77 | TSHR (0.50) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL15063759 | 0.76 | TSHR (0.45) | TSHRLMNAGAAMAPTALDH1A1 | |
| SCHEMBL18513526 | 0.76 | TSHR (0.45) | TSHRLMNAGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874109-A | Novel alpha-cyano-beta-amino acrylate compound and synthetic method thereof | 福建师范大学 | 2022-08-09 | — | — | CN | disclosed |
| EP-3184525-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3184525-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3184525-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CABOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3184525-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CABOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2797916-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2797916-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013101954-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013101954-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | TSHR 2014/4885LMNA 4821/4885GAA 2473/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | TSHR 1514/4885LMNA 4827/4885GAA 2232/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | TSHR 2014/4885LMNA 4821/4885GAA 2473/4885 |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | REN, JAK2, FGFR1 | TSHR 618/4885LMNA 2313/4885GAA 2745/4885 |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | TSHR 2171/4885LMNA 4829/4885GAA 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.